BICO Group AB

BICO reported Q2 2026 revenue of SEK 336m (organic +7%) and a strong improvement in profitability: adjusted EBITDA margin 6% (vs. −2.6% year earlier) and gross margin 59% (vs. 44%). The company cites product mix and more direct sales as drivers, introduced new products and turned net debt into net cash of SEK 207m. Operating cash flow remained negative; net working capital fell to 10% of revenue for the last 12 months. The stock rose in pre-market trading by about 13% to $18.86, with investors viewing the margin and balance-sheet improvements positively. » Más en de.investing.com

BICO reports Q3 2025 net sales of SEK 387m (+5% reported, +12% organic) and adjusted EBITDA of SEK 17m (margin 5%). The main driver was the Lab Automation segment with 35% organic growth and large orders from Biosero; Life Science Solutions grew moderately. Through the sale of MatTek and Visikol, BICO increased cash reserves to SEK 1,241m, despite non-cash impairments on Discover ECHO and Biosero. Management confirms a long-term growth guidance of around 10% CAGR and emphasizes a focus on lab automation and operational efficiency. » Más en de.investing.com

BICO Group reported Q2 2025 revenue of USD 324 million (forecast USD 430.73 million), organic growth of -17% and adjusted EBITDA of -49 million USD, after which the stock fell about 22%. The company is selling non-core assets, increasing its cash reserve to USD 1.4 billion and shifting its focus from academic customers to pharma and biotech markets. Management emphasizes a strategic realignment and measures to improve operational efficiency but sees risks from macroeconomic uncertainty and a weak academic market. » Más en de.investing.com